Advances in the management of bone metastases

.S. Bruland
In the October 15th issue of "Clinical Cancer Research" a separate section is devoted to the proceedings from "The First Cambridge Conference on Advances in Treating Metastatic Bone Cancer" - an expert meeting held in Boston. Among the articles from invited leading scientist in the field is a review of a novel treatment option pioneered by the group of professor Øyvind Bruland, including the first results from a randomized phase II clinical trial in patients with hormone refractory prostate cancer and skeletal metastases.
The review by Bruland et al. outlines the use of external beam radiotherapy, approved bone-seeking radiopharamaceuticals and an update on the clinical results using Alpharadin - a novel bone-seeker; currently in phase II clinical testing in patients with bone metastases from hormone refractory prostate cancer.

Interestingly, the technology is based on Radium and pioneered at The Norwegian Radium Hospital by Bruland and Roy H. Larsen (Larsen is currently a guest scientist at Department of Radiation Biology). The treatment utilizes the unique radiobiological and bone-seeking properties of the alpha-emitting radioisotope Radium-223 (AlpharadinR).


Professor Øyvind S. Brulands home page -

Bruland OS, Nilsson S, Fisher DR, Larsen RH.
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6250s-6257s. (link to PubMed)

Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L.
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6209s-6212s. (link to PubMed)